Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00658372 · ClinicalTrials.gov registry record · Phase 3
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
NCT00658372 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 360 participants.
The verdict
NCT00658372, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
Study Summary
This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects, ages 18 to 65, with generalized anxiety disorder.
Interventions
- DRUG Placebo
- DRUG Paroxetine
- DRUG PD 0332334
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00658372
The ClinicalTrials.gov registry entry for NCT00658372 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00658372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00658372 about?
NCT00658372 is a clinical study titled "A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)". This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects, ages 18 to 65, with generalized anxiety disorder.
What is the current status of trial NCT00658372?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2008-05. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00658372?
The interventions under investigation include: Placebo (DRUG), Paroxetine (DRUG), PD 0332334 (DRUG).
Who is sponsoring clinical trial NCT00658372?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.